Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Main Article Content

Andreas Wollenberg
Ludwig Maximilian University of Munich, Department of Dermatology and Allergy, Munich, Germany; Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium

Michael Cork
Sheffield Dermatology Research, Department of Infection, Immunity, and Cardiovascular Disease, The University of Sheffield and Sheffiel d T eaching Hospitals, NIHR Clinical Research Facility, Sheffield, UK

Carsten Flohr
Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, UK

Anthony Bewley
Barts Health NHS Trust, London, UK

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Chih-ho Hong
University of British Columbia, Vancouver, BC, Canada

Shinichi Imafuku
Fukuoka University, Fukuoka, Japan

Marie L.A. Schuttelaar
University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

Eric Simpson
Oregon Health & Science University, Portland, OR, USA;

Weily Soong
Allervie Health Alabama Allergy & Asthma Center, Birmingham, AL, USA

Petra Amoudruz
LEO Pharma A/S, Ballerup, Denmark

Katja Wendicke Lophaven
LEO Pharma A/S, Ballerup, Denmark

Azra Kurbasic
LEO Pharma A/S, Ballerup, Denmark

Lise Soldbro
LEO Pharma A/S, Ballerup, Denmark

Natacha Strange Vest
LEO Pharma A/S, Ballerup, Denmark

Amy Paller
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

Keywords

atopic dermatitis, tralokinumab

References

1. Peters AS, et al. J Allergy Clin Immunol. 2010;126:590-95.

2. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.

3. Bieber T. Allergy. 2020;75:54-62.

4. Furue K, et al. Immunology. 2019;158:281-86.

5. Szegedi K, et al. JEADV. 2015;29:2136-44.

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480-89.

7. Popovic B, et al. J Mol Biol. 2017;429:208-19.

8. Paller A, et al. 2021 Fall Clinical Dermatology Conference.

9. Wollenberg A et al. Br J Dermatol. 2021;184:437-49.

10. Silverberg JI et al. Br J Dermatol. 2021;184:450-63.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.140

Article Details

How to Cite
[1]
Wollenberg, A., Cork, M., Flohr, C., Bewley, A., Blauvelt, A., Hong, C.- ho, Imafuku, S., Schuttelaar, M.L., Simpson, E., Soong, W., Amoudruz, P., Wendicke Lophaven, K. , Kurbasic, A., Soldbro, L., Strange Vest, N. and Paller, A. 2023. Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s140. DOI:https://doi.org/10.25251/skin.7.supp.140.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>